Viagra vs Vardenafil (Levitra/Staxyn): Combining the Two, Rationale and Risk

What Are Sildenafil and Vardenafil, and How Do They Work?

Both sildenafil and vardenafil block PDE5, the enzyme that breaks down cyclic GMP (cGMP) in smooth muscle cells lining penile arteries. When sexual stimulation triggers nitric oxide release, cGMP accumulates and relaxes vascular smooth muscle, allowing blood flow into the corpus cavernosum. PDE5 inhibition prolongs that effect. Neither drug works without sexual arousal.

Sildenafil was the first PDE5 inhibitor approved by the FDA, receiving approval in March 1998. The landmark Goldstein et al. Trial (N=532) published in the New England Journal of Medicine demonstrated that sildenafil produced significantly improved erections compared with placebo across men with organic, psychogenic, and mixed ED [1]. That single paper redefined how medicine approached erectile dysfunction treatment.

Molecular Potency: Why Vardenafil Works at Lower Doses

Vardenafil's IC50 for PDE5 is roughly 0.1 nM, compared with sildenafil's IC50 of approximately 3.9 nM, making vardenafil about 10 times more potent on a molar basis [2]. This difference explains why effective clinical doses of vardenafil are lower in milligrams. A 10 mg vardenafil tablet is broadly comparable in effect to a 50 mg sildenafil tablet, though direct dose equivalences are approximate and individual response varies.

Selectivity Differences Between the Two Drugs

Vardenafil is also modestly more selective for PDE5 over PDE6, the phosphodiesterase isoform found in retinal photoreceptors. Inhibition of PDE6 is responsible for the transient color-vision changes (blue-tinged vision, increased light sensitivity) reported by some sildenafil users. Vardenafil users report these visual side effects less frequently, which matters clinically for patients who found sildenafil's visual side effects new [2].

Pharmacokinetics: Onset, Duration, and Food Effects

Onset and duration are comparable between the two drugs, but food interactions differ in a clinically meaningful way.

Sildenafil and the High-Fat Meal Problem

Sildenafil reaches peak plasma concentration (Tmax) in approximately 60 minutes under fasted conditions. A high-fat meal delays Tmax by approximately 60 additional minutes and reduces peak plasma concentration (Cmax) by 29% [3]. That delay is significant enough to frustrate men who take the tablet after a restaurant dinner. Patients who report "Viagra stopped working" are often describing this food-drug interaction rather than true pharmacologic non-response.

Vardenafil's More Forgiving Absorption

Vardenafil's Tmax under fasted conditions is 30 to 120 minutes. A high-fat meal delays Tmax by 60 minutes and reduces Cmax by approximately 20%, which is less impactful than sildenafil's interaction [2]. Staxyn, the orally disintegrating tablet formulation of vardenafil, has different absorption pharmacokinetics than the film-coated Levitra tablet. Staxyn 10 mg produces a higher Cmax than Levitra 10 mg, and because it dissolves sublingually without water, it may be preferred by men who find swallowing tablets inconvenient.

Half-Life and Window of Opportunity

Both drugs share a plasma half-life of approximately 4 to 5 hours, giving a practical erectile-response window of 4 to 6 hours. Neither competes with tadalafil's 36-hour window, which remains the reason many men prefer tadalafil for spontaneity. Men who require flexibility beyond 6 hours should discuss tadalafil rather than higher doses of either sildenafil or vardenafil.

Efficacy Comparison: Head-to-Head Evidence

What the Porst 2003 Trial Found

The most cited head-to-head efficacy comparison is Porst et al. (2003), a randomized crossover trial comparing vardenafil 20 mg, sildenafil 50 mg, and placebo in men with mild-to-moderate ED. Vardenafil 20 mg produced successful intercourse in 71% of attempts, compared with 61% for sildenafil 50 mg and 43% for placebo [2]. The authors noted the dose comparison was not milligram-equivalent, so the trial does not prove vardenafil is superior. It does confirm both drugs outperform placebo by a wide margin.

Responder vs. Non-Responder Profiles

A subset of men who fail sildenafil will respond to vardenafil, and vice versa. A 2005 observational analysis estimated that roughly 40 to 50% of sildenafil non-responders achieve satisfactory erections when switched to another PDE5 inhibitor [4]. The reasons are partly pharmacokinetic (better absorption under the patient's usual dietary habits), partly receptor-level differences in individual PDE5 expression, and partly the psychological effect of a genuinely new treatment. Men classified as sildenafil non-responders should be assessed for correct dosing, correct timing, and organic cause severity before being labeled true PDE5 inhibitor treatment failures.

Side-Effect Profiles: Where the Drugs Diverge

Both drugs share a class-level side-effect profile driven by PDE5 inhibition in vascular beds outside the penis.

Overlapping Side Effects

Common side effects shared by sildenafil and vardenafil include headache (10 to 16%), facial flushing (10 to 13%), nasal congestion (4 to 9%), and dyspepsia (3 to 10%) [3]. These arise from vasodilation in non-penile vascular beds where PDE5 is expressed. Rates are dose-dependent for both drugs.

Where Vardenafil Differs

Vardenafil carries an FDA label warning about QTc interval prolongation, an electrocardiographic finding that increases risk of serious ventricular arrhythmia [5]. This is absent from sildenafil's label. Men with a personal or family history of long QT syndrome, or those taking Class IA or Class III antiarrhythmics (quinidine, sotalol, amiodarone), should not use vardenafil. Sildenafil is preferred in those individuals.

Sildenafil produces visual side effects (chromatopsia, photophobia) more often than vardenafil does, due to greater PDE6 inhibition. Men on high doses of sildenafil who report these visual disturbances may find vardenafil better tolerated.

The Combination Question: Why Combining Sildenafil and Vardenafil Has No Rationale

This is the question that drives a significant share of search traffic, often from men who feel one drug is insufficient and wonder whether doubling up could help. The short answer: it cannot help, and it may cause serious harm.

Pharmacodynamic Redundancy

Both drugs act on the same molecular target via the same mechanism. PDE5 enzyme sites are saturable. Once PDE5 is adequately inhibited by one drug at therapeutic dose, adding a second PDE5 inhibitor does not produce additional cGMP accumulation or improved penile blood flow [6]. The ceiling effect is biological, not psychological.

The HealthRX clinical team uses a three-gate framework before any PDE5 inhibitor change is considered:

Gate 1, Dose optimization: Has the patient tried the highest label-approved dose of the current agent (sildenafil 100 mg, vardenafil 20 mg) at least four times under fasted or low-fat conditions, with adequate sexual stimulation?

Gate 2, Timing correction: Is the drug being taken 30 to 60 minutes before intercourse, not immediately before?

Gate 3, Organic severity assessment: Has the prescriber ruled out severe arterial insufficiency, uncontrolled diabetes, or hypogonadism as primary drivers of non-response?

If a man passes all three gates and still fails, the appropriate next step is switching to a different PDE5 inhibitor or escalating to an alternative therapy such as intracavernosal alprostadil. Combining two PDE5 inhibitors skips this framework entirely and introduces risk without any mechanistic benefit.

Additive Hypotension Risk

PDE5 inhibitors produce systemic vasodilation. Single-drug hypotension events, including syncopal episodes and orthostatic hypotension, are documented in the prescribing information for both agents [3][5]. Combining sildenafil and vardenafil would be expected to produce additive blood-pressure lowering, with the potential for severe symptomatic hypotension, pre-syncope, and falls. No published trial has deliberately studied this combination in humans, because the risk-benefit calculation does not justify exposing study participants to it.

The Nitrate Interaction Becomes Doubly Relevant

Both drugs are absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) because nitrates also generate nitric oxide, and the combination can produce catastrophic, potentially fatal hypotension. A man taking both sildenafil and vardenafil who later receives emergency nitroglycerin for chest pain faces compounded pharmacodynamic interaction. Emergency physicians need to know about PDE5 inhibitor use, and a patient on two of them simultaneously creates a clinical communication hazard [3][5].

Switching From Viagra to Vardenafil (or Vardenafil to Viagra): How It Is Done

Switching is a legitimate and sometimes clinically indicated decision. It should always be sequential, with a full washout period between the last dose of the old drug and the first dose of the new one.

Washout Period Required

Both sildenafil and vardenafil have elimination half-lives of approximately 4 to 5 hours. Five half-lives (approximately 20 to 25 hours) reduces plasma concentration to less than 3% of peak. A practical washout of 24 hours is sufficient for a standard-dose switch in a man with normal hepatic and renal function. Men with hepatic impairment (Child-Pugh B) have significantly higher sildenafil exposure due to reduced CYP3A4 clearance, and their washout period should be discussed with a physician individually [3].

Starting Dose When Switching

The general principle is to begin the new agent at the middle label dose:

• Switching to sildenafil: start at 50 mg
• Switching to vardenafil (Levitra): start at 10 mg
• Switching to vardenafil (Staxyn): 10 mg ODT is the only available dose

Dose titration can occur after two to three attempts. Men should not titrate up after a single attempt that failed due to incorrect timing or a high-fat meal.

Who Should Consider Switching to Vardenafil

Sildenafil users who may benefit from switching to vardenafil include men who:

• Experience significant visual side effects (chromatopsia) on sildenafil 50 mg or 100 mg
• Have difficulty with sildenafil's strict food timing requirements
• Have a documented suboptimal response to sildenafil 100 mg after four properly timed, fasted-state attempts
• Prefer an orally disintegrating tablet (Staxyn) for convenience or swallowing difficulties

Who Should Consider Switching to Sildenafil

Vardenafil users who may benefit from switching to sildenafil include men who:

• Have a baseline QTc prolongation or are taking drugs that extend QTc
• Are taking Class IA antiarrhythmics where vardenafil is contraindicated
• Experience inadequate response at vardenafil 20 mg and wish to try sildenafil 100 mg before escalating to non-oral therapies
• Have insurance or cost constraints, since generic sildenafil is widely available at significantly lower cost than branded Levitra

Drug Interactions Beyond Nitrates

Both drugs are metabolized primarily by CYP3A4, with minor contributions from CYP2C9 for sildenafil. This shared metabolic pathway creates common drug-interaction risk.

Alpha-Blocker Co-Administration

Alpha-adrenergic blockers (tamsulosin, doxazosin, terazosin) used for benign prostatic hyperplasia lower blood pressure through a different mechanism. Combining either PDE5 inhibitor with an alpha-blocker increases hypotension risk. The FDA labels for both drugs recommend caution and, specifically for vardenafil, advise a 6-hour gap between an alpha-blocker dose and the vardenafil dose [5].

CYP3A4 Inhibitors

Strong CYP3A4 inhibitors (ritonavir, ketoconazole, clarithromycin, grapefruit juice in large quantities) dramatically increase plasma levels of both sildenafil and vardenafil. Men on ritonavir-based HIV regimens should not exceed sildenafil 25 mg in 48 hours; vardenafil is contraindicated with ritonavir [3][5]. These are not theoretical concerns. Men who take an HIV-based protease inhibitor cocktail and use a standard recreational dose of sildenafil have presented with prolonged erections (priapism) and severe hypotension.

Special Populations: Diabetes, Hypogonadism, and Post-Prostatectomy ED

Diabetic Men

ED prevalence in men with type 2 diabetes is 50 to 75%, approximately three times the rate in age-matched non-diabetic men [7]. Both sildenafil and vardenafil have been studied specifically in diabetic ED populations. Vardenafil 10 mg and 20 mg produced significant improvements in IIEF (International Index of Erectile Function) scores compared with placebo in a dedicated diabetic ED trial, with 57% of men on vardenafil 20 mg achieving successful intercourse vs. 23% on placebo (P<0.001) [8]. Sildenafil data in diabetic men shows similar, though slightly lower, success rates, partly attributed to the greater degree of autonomic neuropathy and vascular disease in this population.

Hypogonadal Men

A testosterone level below 300 ng/dL is independently associated with poor PDE5 inhibitor response. The likely mechanism involves testosterone's role in upregulating penile NOS (nitric oxide synthase) expression [9]. Men who fail both sildenafil and vardenafil at maximum doses should have a morning total testosterone measured. Correcting hypogonadism with testosterone therapy often restores PDE5 inhibitor response in men who previously appeared refractory.

Post-Radical Prostatectomy

Nerve-sparing radical prostatectomy preserves some erectile function in 30 to 80% of men depending on surgical technique and baseline function [10]. Both sildenafil and vardenafil have shown benefit in this population, but response rates are lower than in non-surgical ED. Nightly low-dose PDE5 inhibitor therapy (penile rehabilitation) is used in some practices; the evidence base for this approach remains debated, with a 2021 Cochrane review finding insufficient evidence to recommend routine penile rehabilitation with PDE5 inhibitors after prostatectomy [10].

Cost and Access: A Practical Consideration

Generic sildenafil has been available in the United States since 2017. A 100 mg tablet of generic sildenafil commonly costs $1, $4 at major pharmacies with discount programs such as GoodRx. Branded Viagra costs approximately $60, $80 per tablet without insurance.

Generic vardenafil became available in the U.S. In 2018. Generic vardenafil 20 mg tablets typically cost $8, $15 each, still substantially more than generic sildenafil. Staxyn (the ODT formulation) does not yet have a widely available generic equivalent and remains branded and expensive.

For men with comparable response to both drugs, the cost difference strongly favors generic sildenafil. The Endocrine Society's clinical practice guideline on male sexual dysfunction recommends considering cost and patient preference when choosing between equally effective agents [9].